UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Biologic treatment in Sjögren's syndrome.
  • Publication Type:
    Journal article
  • Publication Sub Type:
    Journal Article
  • Authors:
    Sada PR, Isenberg D, Ciurtin C
  • Publication date:
    02/2015
  • Pagination:
    219, 230
  • Journal:
    Rheumatology (Oxford)
  • Volume:
    54
  • Issue:
    2
  • Status:
    Published
  • Country:
    England
  • PII:
    keu417
  • Language:
    eng
  • Keywords:
    B cell-targeted therapy, Sjögren’s syndrome, T cell modulation therapy, abatacept, belimumab, biologic therapies, epratuzumab, interferon, rituximab, Adult, Animals, Antibodies, Monoclonal, Antirheumatic Agents, B-Cell Activating Factor, Biological Factors, Biological Products, Biological Therapy, Cytokines, Epidemiologic Methods, Humans, Mice, Molecular Targeted Therapy, Sjogren's Syndrome, T-Lymphocytes
Abstract
SS is a chronic systemic autoimmune disease characterized by decreased exocrine gland function. A variety of other disease manifestations may also be present, including general constitutional symptoms and extraglandular features. A multidisciplinary approach focused on both local and systemic medical therapies is needed as the disease has a wide clinical spectrum. The current treatment for SS is mainly symptomatic. However, there is evidence that systemic drugs are effective in controlling extraglandular manifestations of the disease. Overall evidence for the role of conventional immunosuppressive therapy is limited. A number of attempts to use biologic therapies have led to variable results. Biologic agents targeting B cells, such as rituximab, epratuzumab and belimumab, have shown promising results, but further studies are needed to validate the findings. Early-phase studies with abatacept and alefacept proved that T cell stimulation inhibition is another potentially effective target for SS treatment. Modulation or inhibition of other targets such as IFN, IL-6 and Toll-like receptor are also currently being investigated. We have summarized the available evidence regarding the efficacy of biologic treatments and discuss other potential therapies targeting pathways or molecules recognized as being involved in the pathogenesis of SS.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by